传统质子切除术后放疗与超分割质子切除术后放疗:随机 2 期试验的患者报告结果

{"title":"传统质子切除术后放疗与超分割质子切除术后放疗:随机 2 期试验的患者报告结果","authors":"","doi":"10.1016/j.ijrobp.2024.07.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose/Objective(s)</h3><div>Proton postmastectomy radiation therapy (PMRT) is under investigation and increasingly used in clinical practice. However, limited prospective health related quality of life data have been reported to assist patients and physicians with treatment decisions. To date studies involving proton PMRT have primarily used conventional fractionation (CF). We evaluated patient reported outcomes from a randomized trial comparing CF and hypofractionation (HF) proton PMRT, including those with immediate breast reconstruction.</div></div><div><h3>Materials/Methods</h3><div>We conducted a randomized phase 2 trial (MC1631) comparing CF (50 Gy in 25 fractions [relative biological effectiveness (RBE) 1.1]) and HF (40.05 Gy in 15 fractions [RBE 1.1]) proton PMRT. Patients were randomly assigned (1:1) to either CF or HF, with presence of immediate reconstruction (yes vs no) as a stratification factor. All patients were treated with pencil-beam scanning. Eligibility criteria included age 18 years or older with breast cancer resected by mastectomy with or without immediate reconstruction with indications for PMRT. Psychosocial well-being, physical well-being, sexual well-being, satisfaction with breasts, and satisfaction with outcomes scores were measured using the condition-specific validated BREAST-Q patient-reported outcome instrument during annual follow-up. Data were analyzed using linear mixed-effects modeling. This trial is registered with ClinicalTrials.gov, NCT02783690.</div></div><div><h3>Results</h3><div>Seventy-four of 82 randomized patients (90%) completed at least one BREAST-Q questionnaire (36 CF, 38 HF). Median age was 53 years (range = 32-78). Fifty-two (70%) had immediate breast reconstruction with tissue expanders (83%), implants (13%), or autologous reconstruction (4%) at the time of PMRT. Fifty-seven (77%) received neoadjuvant and/or adjuvant chemotherapy. At 36 months, mean score (95% CI) of patient-reported satisfaction (mastectomy) was 59.5 (51.2-67.8) for CF and 61.0 (95% CI = 52.5-69.5) for HF. Amongst patients with reconstruction, similar satisfaction with breasts (63.9 [95% CI = 55.9-71.9] vs 59.0 [95% CI = 51.1-66.8]) and satisfaction with outcome (70.3 [95% CI = 60.0-80.7] vs 70.5 [95% CI = 60.0-81.0]) scores were observed for the CF and HF arms, respectively. No significant differences were also observed for psychosocial well-being, physical well-being, and sexual well-being.</div></div><div><h3>Conclusion</h3><div>CF and HF proton PMRT yield similar patient reported satisfaction and well-being at 3 years of follow up.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conventional vs. Hypofractionated Proton Postmastectomy Radiotherapy: Patient Reported Outcomes from a Randomized Phase 2 Trial\",\"authors\":\"\",\"doi\":\"10.1016/j.ijrobp.2024.07.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose/Objective(s)</h3><div>Proton postmastectomy radiation therapy (PMRT) is under investigation and increasingly used in clinical practice. However, limited prospective health related quality of life data have been reported to assist patients and physicians with treatment decisions. To date studies involving proton PMRT have primarily used conventional fractionation (CF). We evaluated patient reported outcomes from a randomized trial comparing CF and hypofractionation (HF) proton PMRT, including those with immediate breast reconstruction.</div></div><div><h3>Materials/Methods</h3><div>We conducted a randomized phase 2 trial (MC1631) comparing CF (50 Gy in 25 fractions [relative biological effectiveness (RBE) 1.1]) and HF (40.05 Gy in 15 fractions [RBE 1.1]) proton PMRT. Patients were randomly assigned (1:1) to either CF or HF, with presence of immediate reconstruction (yes vs no) as a stratification factor. All patients were treated with pencil-beam scanning. Eligibility criteria included age 18 years or older with breast cancer resected by mastectomy with or without immediate reconstruction with indications for PMRT. Psychosocial well-being, physical well-being, sexual well-being, satisfaction with breasts, and satisfaction with outcomes scores were measured using the condition-specific validated BREAST-Q patient-reported outcome instrument during annual follow-up. Data were analyzed using linear mixed-effects modeling. This trial is registered with ClinicalTrials.gov, NCT02783690.</div></div><div><h3>Results</h3><div>Seventy-four of 82 randomized patients (90%) completed at least one BREAST-Q questionnaire (36 CF, 38 HF). Median age was 53 years (range = 32-78). Fifty-two (70%) had immediate breast reconstruction with tissue expanders (83%), implants (13%), or autologous reconstruction (4%) at the time of PMRT. Fifty-seven (77%) received neoadjuvant and/or adjuvant chemotherapy. At 36 months, mean score (95% CI) of patient-reported satisfaction (mastectomy) was 59.5 (51.2-67.8) for CF and 61.0 (95% CI = 52.5-69.5) for HF. Amongst patients with reconstruction, similar satisfaction with breasts (63.9 [95% CI = 55.9-71.9] vs 59.0 [95% CI = 51.1-66.8]) and satisfaction with outcome (70.3 [95% CI = 60.0-80.7] vs 70.5 [95% CI = 60.0-81.0]) scores were observed for the CF and HF arms, respectively. No significant differences were also observed for psychosocial well-being, physical well-being, and sexual well-being.</div></div><div><h3>Conclusion</h3><div>CF and HF proton PMRT yield similar patient reported satisfaction and well-being at 3 years of follow up.</div></div>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0360301624007739\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624007739","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的/目标:质子乳房切除术后放射治疗(PMRT)正在接受研究,并越来越多地应用于临床实践。然而,用于帮助患者和医生做出治疗决定的前瞻性健康相关生活质量数据却十分有限。迄今为止,涉及质子 PMRT 的研究主要使用常规分次法(CF)。材料/方法 我们进行了一项随机 2 期试验(MC1631),比较了 CF(50 Gy,25 次分次[相对生物效应(RBE)1.1])和 HF(40.05 Gy,15 次分次[RBE 1.1])质子 PMRT。患者被随机分配(1:1)至CF或HF,并将是否立即重建(是与否)作为分层因素。所有患者均接受铅笔束扫描治疗。资格标准包括年龄在18岁或18岁以上,乳房切除术切除的乳腺癌,有或没有立即重建,有PMRT适应症。在年度随访期间,使用针对特定情况的有效 BREAST-Q 患者报告结果工具测量了患者的社会心理健康、身体健康、性健康、对乳房的满意度以及对结果的满意度。数据采用线性混合效应模型进行分析。该试验已在 ClinicalTrials.gov 登记,编号为 NCT02783690。结果82 名随机患者中有 74 名(90%)至少完成了一份 BREAST-Q 问卷(36 名 CF,38 名 HF)。中位年龄为 53 岁(范围 = 32-78)。52名患者(70%)在接受PMRT时立即进行了乳房重建,包括组织扩张器(83%)、植入物(13%)或自体重建(4%)。57人(77%)接受了新辅助和/或辅助化疗。在36个月时,患者报告的满意度(乳房切除术)平均得分(95% CI)为:CF为59.5(51.2-67.8),HF为61.0(95% CI = 52.5-69.5)。在接受乳房再造的患者中,CF 和 HF 两组的乳房满意度(63.9 [95% CI = 55.9-71.9] vs 59.0 [95% CI = 51.1-66.8])和结果满意度(70.3 [95% CI = 60.0-80.7] vs 70.5 [95% CI = 60.0-81.0])评分相似。结论CF和HF质子PMRT在随访3年后患者报告的满意度和幸福感相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Conventional vs. Hypofractionated Proton Postmastectomy Radiotherapy: Patient Reported Outcomes from a Randomized Phase 2 Trial

Purpose/Objective(s)

Proton postmastectomy radiation therapy (PMRT) is under investigation and increasingly used in clinical practice. However, limited prospective health related quality of life data have been reported to assist patients and physicians with treatment decisions. To date studies involving proton PMRT have primarily used conventional fractionation (CF). We evaluated patient reported outcomes from a randomized trial comparing CF and hypofractionation (HF) proton PMRT, including those with immediate breast reconstruction.

Materials/Methods

We conducted a randomized phase 2 trial (MC1631) comparing CF (50 Gy in 25 fractions [relative biological effectiveness (RBE) 1.1]) and HF (40.05 Gy in 15 fractions [RBE 1.1]) proton PMRT. Patients were randomly assigned (1:1) to either CF or HF, with presence of immediate reconstruction (yes vs no) as a stratification factor. All patients were treated with pencil-beam scanning. Eligibility criteria included age 18 years or older with breast cancer resected by mastectomy with or without immediate reconstruction with indications for PMRT. Psychosocial well-being, physical well-being, sexual well-being, satisfaction with breasts, and satisfaction with outcomes scores were measured using the condition-specific validated BREAST-Q patient-reported outcome instrument during annual follow-up. Data were analyzed using linear mixed-effects modeling. This trial is registered with ClinicalTrials.gov, NCT02783690.

Results

Seventy-four of 82 randomized patients (90%) completed at least one BREAST-Q questionnaire (36 CF, 38 HF). Median age was 53 years (range = 32-78). Fifty-two (70%) had immediate breast reconstruction with tissue expanders (83%), implants (13%), or autologous reconstruction (4%) at the time of PMRT. Fifty-seven (77%) received neoadjuvant and/or adjuvant chemotherapy. At 36 months, mean score (95% CI) of patient-reported satisfaction (mastectomy) was 59.5 (51.2-67.8) for CF and 61.0 (95% CI = 52.5-69.5) for HF. Amongst patients with reconstruction, similar satisfaction with breasts (63.9 [95% CI = 55.9-71.9] vs 59.0 [95% CI = 51.1-66.8]) and satisfaction with outcome (70.3 [95% CI = 60.0-80.7] vs 70.5 [95% CI = 60.0-81.0]) scores were observed for the CF and HF arms, respectively. No significant differences were also observed for psychosocial well-being, physical well-being, and sexual well-being.

Conclusion

CF and HF proton PMRT yield similar patient reported satisfaction and well-being at 3 years of follow up.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy. ORAI2 is Important for the Development of Early-Stage Post-Irradiation Fibrosis in Salivary Glands. Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs) Contralateral Neck Recurrence Rates in Head and Neck Carcinomas after Primary Surgery, Bilateral Neck Dissection, a Pathologically Negative Contralateral Neck, and Adjuvant Ipsilateral Neck Radiation Phase II Trial of Proton Re-Irradiation+/-Chemotherapy in Previously Irradiated Recurrent Head/Neck Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1